Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization

Human Gene Therapy

Volumn 12, Issue 10, 2001, Pages 1299-1310

  Lai, C M ^a   Brankov, M ^b   Zaknich, T ^b   Lai, Y K Y ^a   Shen, W Y ^a   Constable, I J ^a   Kovesdi, I ^c   Rakoczy, P E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c GENVEC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA GALACTOSIDASE; RECOMBINANT DNA; SFLT 1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUTERIZATION; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CORNEA NEOVASCULARIZATION; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TRABECULAR MESHWORK; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANIMALS; BETA-GALACTOSIDASE; BLOTTING, WESTERN; CELL LINE; CORNEA; CORNEAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; EYE; GENETIC VECTORS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; NITRATES; POTASSIUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; SILVER NITRATE; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES; UMBILICAL VEINS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0034919401     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401750270959     Document Type: Article

References (50)

1. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
2. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in nonhuman primate
3. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other ocular diseases
4. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
5. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
6. Elevated gamma-aminobutyric acid, glutamate and vascular endothelial growth factor level in the vitreous of patients with proliferative diabetic retinopathy
7. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy
8. Physical mapping of a large-plaque mutation of adenovirus type 2
9. A human retinal pigment epithelial cell line that retains epithelial characteristics after prolonged culture
10. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC beta inhibition with LY333531
11. The Fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
12. Vascular permeability factor/vascular endothelial growth factor microvascular hyperpermeability and angiogenesis
13. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea
14. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
15. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes
16. Paracrine expression of a native soluble vascular endothelial growth factor inhibits tumour growth, metastasis, and mortality rate
17. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector
18. Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery
19. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: A role for VEGF and possible treatment for SRN in age-related macular degeneration
20. Expression of vascular endothelial growth factor in experimental choroidal neovascularization
21. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor
22. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor
23. Identification of a natural soluble form of the vascular endothelial growth factor receptor, Flt-1, and its heterodimerization with KDR
24. Solute permeability of the corneal endothelium and Descemet's membrane
25. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
26. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470
27. Regional suppression of tumour growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the Flt-1 vascular endothelial growth factor receptor
28. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
29. Preferential adenovirus-mediated transduction of cells at the sites of laser photocoagulation in the rat eye
30. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
31. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular neovascularization in a primate model
32. Increased serum level of vascular endothelial cell growth factor in human crescentic glomerulonephritis
33. Blockade of vascular endothelial growth factor receptor signaling is sufficient to completely prevent retinal neovascularization
34. Vascular endothelial growth factor upregulation in human central vein occlusion
35. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas
36. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization
37. Expression of cathepsin S antisense transcripts by adenovirus in retinal pigment epithelial cells
38. Oligonucleotides inhibit retinal neovascularization in a murine models of proliferative retinopathy
39. Evaluation of adeno-associated virus mediated gene transfer into the rat retina by clinical fluorescence photography
40. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
41. Vascular permeability factor (VPF, VEGF) in tumour biology
42. Expression of cell adhesion molecules and vascularization growth factor in experimental choroidal neovascularization in the rat
43. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization
44. Widespread long-term transfer to mouse skeletal muscles and heart
45. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor
46. Vascular endothelial cell growth factor, a potent and selective angiogenic agent
47. Adenovirus-mediated gene transfer to the ocular surface epithelium
48. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularization
49. Effect of a topically applied neutralising antibody against vascular endothelial growth factor on corneal allograft rejection of rat